Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on World Healthcare Report.
Press releases published on June 4, 2025
Synergy CHC Announces New $20 Million Long-Term Credit Facility
GlobeNewswire
·
June 4, 2025
WESTBROOK, Maine, June 04, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ: SNYR) (“Synergy” or the “Company”), a provider of consumer health care and lifestyle products, announced today that it has entered into a $20 million term loan credit agreement, …
ViaDerma, Inc. Confirms Ongoing Operations and Commitment to Regulatory Compliance
GlobeNewswire
·
June 4, 2025
LOS ANGELES, June 04, 2025 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC Expert Market: VDRM), a specialty pharmaceutical company, today announced that it remains fully operational and is actively working to complete its overdue annual and quarterly financial …
Conduit Pharmaceuticals Enters Joint Development Agreement with Manoira to Advance AZD1656 and AZD5658 in Animal Health
GlobeNewswire
·
June 4, 2025
Collaboration leverages cutting-edge reformulation expertise to generate cross-species insights, fast-track human clinical programs, and seeks to capture commercial potential in the $15 billion animal health market Evaluation of AZD5658 expands Conduit’s …
BioSig & Streamex Appoint Co-Founder of the Osisko Group & Mining Visionary, Sean Roosen as Strategic Advisor
GlobeNewswire
·
June 4, 2025
Los Angeles, CA and Vancouver, BC, June 04, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig”), which acquired Streamex Exchange Corporation as its wholly owned subsidiary (“Streamex”) in May 2025, is pleased to announce the …
HCW Biologics Completes Deliverable and Solidifies License Agreement with WY Biotech
GlobeNewswire
·
June 4, 2025
MIRAMAR, Fla., June 04, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (“HCWB” or “HCW Biologics”), (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by …
FOXO TECHNOLOGIES INC. COMPLETES EQUITY FUNDING AGREEMENT
GlobeNewswire
·
June 4, 2025
WEST PALM BEACH, FLORIDA, June 04, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (“FOXO” or the “Company”) today announced that it has executed an agreement to issue 1,650 of its Series A Cumulative Convertible Redeemable Preferred …
Cellectar Granted U.S. FDA Breakthrough Therapy Designation for Iopofosine I 131 in Waldenstrom Macroglobulinemia (WM)
GlobeNewswire
·
June 4, 2025
Designation Supported by CLOVER WaM Phase 2 Study Data Which Reported an 83.6% Overall Response Rate (ORR) Seeking Guidance from EMA to Determine if CLOVER WaM Phase 2 Data Meets Criteria to Apply for Fast-Track, Conditional Marketing Authorization, Answer …
Consilium Releases 2025 Trends in Locum Tenens Report, Revealing Data-Driven Insights for Healthcare Success
EIN Presswire
·
June 4, 2025
Consilium shares insights that demonstrate their ongoing commitment to excellence in healthcare staffing success. IRVING, TX, UNITED STATES, June 3, 2025 /EINPresswire.com/ -- Consilium today announced the release of its comprehensive 2025 Trends in …
Dino Miliotis Reframes the AI Conversation in Modern Healthcare
EIN Presswire
·
June 4, 2025
Tech Frontman and Recovery Advocate Calls for Clarity, Ethics, and Smarter Tools—Not Human Replacement. CHICAGO, IL, UNITED STATES, June 3, 2025 /EINPresswire.com/ -- As public anxiety over artificial intelligence grows, recovery advocate and OpiAID …
Radiopharm Theranostics Doses First Patient in Phase 1 ‘HEAT’ Trial of 177Lu-RAD202 for Treatment of Advanced HER2-Positive Solid Tumors
GlobeNewswire
·
June 4, 2025
Phase 11 First-In-Human study designed to assess safety, tolerability, right dose for Phase 2 and early signs of efficacy of 177Lu-RAD202 in individuals with advanced HER2-positive solid tumors Previous clinical proof-of concept data2 for targeting HER-2 …
Allarity Therapeutics Announces Research Collaboration with Indiana Biosciences Research Institute to Further Advance Understanding of Stenoparib’s Unique, Dual Therapeutic Mechanism of Action
GlobeNewswire
·
June 4, 2025
TARPON SPRINGS, Fla., June 4, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—as …
Elicio Therapeutics Secures $10 Million in Financing
GlobeNewswire
·
June 4, 2025
Funding expected to support operations into Q1 2026. Anticipated AMPLIFY-7P Phase 2 interim analysis expected in Q3 2025. BOSTON, June 04, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage …
BeautyHealth Surpasses 35,000 Hydrafacial Devices Worldwide Reflecting Growing Consumer Demand for Clinically Proven Skin Health Treatments
GlobeNewswire
·
June 4, 2025
LONG BEACH, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- The BeautyHealth Company (NASDAQ: SKIN), home to flagship brand Hydrafacial™, recently achieved a major milestone with 35,000 Hydrafacial devices installed worldwide, reinforcing its market leadership …
Daré Bioscience and Rosy Wellness Announce Strategic Collaboration to Educate and Market Daré’s DARE to PLAY Sildenafil Cream
GlobeNewswire
·
June 4, 2025
Collaboration will leverage Rosy Wellness’ extensive reach and community of over 250,000 women Rosy Wellness is a multi-award winning app recommended by 8,000+ healthcare professionals Daré expects to start recording revenue in the 4th quarter this year …
Vadadustat U.S. Patient Data from Global Phase 3 Clinical Program Published in Journal of the American Society of Nephrology
GlobeNewswire
·
June 4, 2025
CAMBRIDGE, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the Journal of the American Society …
aTyr Pharma Announces Findings from Interim Analysis of Ongoing Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD)
GlobeNewswire
·
June 4, 2025
Three out of four efzofitimod-treated diffuse SSc-ILD patients showed clinically important improvement based on the modified Rodnan Skin Score (mRSS) assessment at 12 weeks. Efzofitimod was generally safe and well tolerated at all doses. SAN DIEGO, June 04 …
Famed Former NFL Safety, Leonard Wheeler, Named Global Ambassador For TULSA-PRO®
GlobeNewswire
·
June 4, 2025
TORONTO, June 04, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, AI-powered, incision-free therapies for the ablation …
BriaCell Announces Virtual Investor Presentations on Thursday, June 12 and Thursday, June 26
GlobeNewswire
·
June 4, 2025
PHILADELPHIA and VANCOUVER, British Columbia, June 04, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ), (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to …
Aveanna Healthcare Holdings Completes Acquisition of Thrive Skilled Pediatric Care
GlobeNewswire
·
June 4, 2025
ATLANTA, June 04, 2025 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH), a leading, diversified home care platform focused on providing care to medically complex, high-cost patient populations, today announced that it completed its …
BrainsWay Announces $5 Million Minority-Stake Investment in Stella MSO, LLC
GlobeNewswire
·
June 4, 2025
BURLINGTON, Mass. and JERUSALEM, June 04, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ …